Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Kathryn L Penney, Sc.D.

Co-Author

This page shows the publications co-authored by Kathryn Penney and Meir Stampfer.
Connection Strength

5.012
  1. Re: Melissa Assel, Anders Dahlin, David Ulmert, et al. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening. Eur Urol 2018;73:961-7. Eur Urol. 2019 03; 75(3):e54-e55.
    View in: PubMed
    Score: 0.783
  2. Association of prostate cancer risk variants with gene expression in normal and tumor tissue. Cancer Epidemiol Biomarkers Prev. 2015 Jan; 24(1):255-60.
    View in: PubMed
    Score: 0.596
  3. Reply to M.M.J. Zanders et al. J Clin Oncol. 2014 Mar 01; 32(7):702-3.
    View in: PubMed
    Score: 0.563
  4. The time is ripe for a randomized trial of metformin in clinically localized prostate cancer. J Clin Oncol. 2013 Sep 01; 31(25):3054-5.
    View in: PubMed
    Score: 0.546
  5. Circulating Insulin-Like Growth Factor 1-Related Biomarkers and Risk of Lethal Prostate Cancer. JNCI Cancer Spectr. 2022 02; 6(1).
    View in: PubMed
    Score: 0.244
  6. Clinical stage provides useful prognostic information even after pathological stage is known for prostate cancer in the PSA era. PLoS One. 2020; 15(6):e0234391.
    View in: PubMed
    Score: 0.220
  7. Prognostic Utility of a New mRNA Expression Signature of Gleason Score. Clin Cancer Res. 2017 Jan 01; 23(1):81-87.
    View in: PubMed
    Score: 0.170
  8. Replication of a genetic variant for prostate cancer-specific mortality. Prostate Cancer Prostatic Dis. 2015 Sep; 18(3):260-3.
    View in: PubMed
    Score: 0.154
  9. Plasma antioxidants, genetic variation in SOD2, CAT, GPX1, GPX4, and prostate cancer survival. Cancer Epidemiol Biomarkers Prev. 2014 Jun; 23(6):1037-46.
    View in: PubMed
    Score: 0.143
  10. Gleason grade progression is uncommon. Cancer Res. 2013 Aug 15; 73(16):5163-8.
    View in: PubMed
    Score: 0.137
  11. Selenoprotein P genetic variants and mrna expression, circulating selenium, and prostate cancer risk and survival. Prostate. 2013 May; 73(7):700-5.
    View in: PubMed
    Score: 0.130
  12. mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol. 2011 Jun 10; 29(17):2391-6.
    View in: PubMed
    Score: 0.117
  13. Association of KLK3 (PSA) genetic variants with prostate cancer risk and PSA levels. Carcinogenesis. 2011 Jun; 32(6):853-9.
    View in: PubMed
    Score: 0.116
  14. Genome-wide association study of prostate cancer mortality. Cancer Epidemiol Biomarkers Prev. 2010 Nov; 19(11):2869-76.
    View in: PubMed
    Score: 0.113
  15. A large prospective study of SEP15 genetic variation, interaction with plasma selenium levels, and prostate cancer risk and survival. Cancer Prev Res (Phila). 2010 May; 3(5):604-10.
    View in: PubMed
    Score: 0.109
  16. Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clin Cancer Res. 2009 May 01; 15(9):3223-30.
    View in: PubMed
    Score: 0.101
  17. Germline variants in IL4, MGMT and AKT1 are associated with prostate cancer-specific mortality: An analysis of 12,082 prostate cancer cases. Prostate Cancer Prostatic Dis. 2018 06; 21(2):228-237.
    View in: PubMed
    Score: 0.046
  18. Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer. Nat Commun. 2017 09 04; 8(1):420.
    View in: PubMed
    Score: 0.045
  19. Genome-wide association study of prostate cancer-specific survival. Cancer Epidemiol Biomarkers Prev. 2015 Nov; 24(11):1796-800.
    View in: PubMed
    Score: 0.039
  20. Molecular differences in transition zone and peripheral zone prostate tumors. Carcinogenesis. 2015 Jun; 36(6):632-8.
    View in: PubMed
    Score: 0.038
  21. GermLine Variation in Superoxide Dismutase-2 (SOD2) and Survival Outcomes After Radiation Therapy for Prostate Cancer: Results of a Test and Validation Set Analysis. Clin Genitourin Cancer. 2015 Aug; 13(4):370-377.e1.
    View in: PubMed
    Score: 0.038
  22. A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet. 2014 Oct; 46(10):1103-9.
    View in: PubMed
    Score: 0.037
  23. Genetic variation across C-reactive protein and risk of prostate cancer. Prostate. 2014 Jul; 74(10):1034-42.
    View in: PubMed
    Score: 0.036
  24. SPINK1 protein expression and prostate cancer progression. Clin Cancer Res. 2014 Sep 15; 20(18):4904-11.
    View in: PubMed
    Score: 0.036
  25. Prostate cancer (PCa) risk variants and risk of fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Eur Urol. 2014 Jun; 65(6):1069-75.
    View in: PubMed
    Score: 0.035
  26. Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG. J Natl Cancer Inst. 2013 Dec 18; 105(24):1881-90.
    View in: PubMed
    Score: 0.035
  27. Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study. Cancer Epidemiol Biomarkers Prev. 2013 Nov; 22(11):1984-93.
    View in: PubMed
    Score: 0.034
  28. Common genetic variation of the calcium-sensing receptor and lethal prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2013 Jan; 22(1):118-26.
    View in: PubMed
    Score: 0.032
  29. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012 Sep; 21(9):1497-509.
    View in: PubMed
    Score: 0.032
  30. Seasonal variation in expression of markers in the vitamin D pathway in prostate tissue. Cancer Causes Control. 2012 Aug; 23(8):1359-66.
    View in: PubMed
    Score: 0.032
  31. Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study. J Natl Cancer Inst. 2012 May 02; 104(9):690-9.
    View in: PubMed
    Score: 0.031
  32. Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2011 Dec; 20(12):2618-27.
    View in: PubMed
    Score: 0.030
  33. Genetic variation in the toll-like receptor 4 and prostate cancer incidence and mortality. Prostate. 2012 Feb 01; 72(2):209-16.
    View in: PubMed
    Score: 0.029
  34. Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J Clin Oncol. 2011 Jun 10; 29(17):2378-85.
    View in: PubMed
    Score: 0.029
  35. Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet. 2010 Nov 11; 6(11):e1001204.
    View in: PubMed
    Score: 0.028
  36. Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival. J Clin Oncol. 2010 Sep 01; 28(25):3958-64.
    View in: PubMed
    Score: 0.028
  37. Genetic variation in RNASEL associated with prostate cancer risk and progression. Carcinogenesis. 2010 Sep; 31(9):1597-603.
    View in: PubMed
    Score: 0.028
  38. Immunohistochemical expression of BRCA1 and lethal prostate cancer. Cancer Res. 2010 Apr 15; 70(8):3136-9.
    View in: PubMed
    Score: 0.027
  39. Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res. 2009 Jul 01; 69(13):5568-74.
    View in: PubMed
    Score: 0.026
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.